03174 CSOP China Healthcare Disruption Index ETF
- 1.788
- -0.034-1.87%
華潤醫藥：公告有關於中國發行中期票據及公司債券的華潤醫藥控股截至2024年3月31日止三個月的未經審核財務業績
Hansoh Pharmaceutical's 2023 Profit Up 27%
Hansoh Pharmaceutical Group (HKG:3692) recorded a 27% rise in attributable profit for 2023 to 3.28 billion yuan from 2.58 billion yuan in 2022, according to the company's annual report. Earnings per s
Cinda Biotech (01801.HK): Total product revenue in the first quarter exceeded 1.7 billion yuan, a strong year-on-year increase of more than 60%
On April 30, Gelonghui | Cinda Biotech (01801.HK) announced that in the first quarter of 2024, the company achieved total product revenue exceeding RMB 1.7 billion, a strong increase of over 60% over the previous year. The overall product portfolio continued to grow rapidly during the quarter, thanks to advantages such as broad indication potential, health insurance coverage and complete access channels. Dabershu (Cindilizumab Injection) continues to achieve strong sales performance and a stable market leading position. Other products have also grown significantly. In particular, new products have accelerated growth and continued to increase their contribution.
Yao Ming Kangde (02359.HK) spent 2005 million yuan to buy back 457,300 A shares on April 30
On April 30, Ge Longhui | Yao Ming Kangde (02359.HK) issued an announcement. On April 30, 2024, it spent RMB 2005 million yuan to repurchase 457,300 A shares, with a repurchase price of 43.57-44.7 yuan per share.
Anectinib fumarate capsules, a Class 1 innovative drug independently developed by China Biopharmaceutical (01177), were approved for marketing
China Biopharmaceutical (01177) announced that the group's self-developed Class 1 innovative drug anectinil fumarate capsules “U...
截至二零二三年十二月三十一日止的經審核賬目
Innovent Biologics Names Samuel Zhang as Global Chief Business Officer
Innovent Biologics Names Samuel Zhang as Global Chief Business Officer
Cinda Biotech Announces Appointment of Dr. Zhang Suhua as Global Chief Commercial Officer
SAN FRANCISCO, SUZHOU, China, April 30, 2024/PRNewswire/ -- Cinda Biopharmaceuticals (HKEx stock code: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for major diseases such as oncology, autoimmunity, metabolism, cardiovascular, and ophthalmology, announced today the appointment of Dr. Samuel Zhang (Samuel Zhang) as Global Chief Commercial Officer (CBO). Dr. Zhang will be responsible for the strategic planning and business development of Cinda Biotech's global business and will report to Dr. Yu Dechao, the founder, chairman and CEO of the company. Dr. Zhang is in
UBS: Maintaining the “neutral” rating of Pharmacovigilance (02359), the target price was reduced to HK$40.1
At present, Yao Ming Kangde's management remains unchanged at the target of revenue of 38.3 billion yuan to 40.5 billion yuan in 2024.
Pharmaceutical Biotech Releases 2023 ESG Report Highlights Strong Commitment to Sustainable Development
The company keeps its promises, takes social responsibility, and works with customers around the world to create long-term value for all stakeholders. The company has made significant progress on climate change, reducing the intensity of Scope 1 and Scope 2 greenhouse gas emissions by 29% compared to the 2020 base year. The company achieved the water saving target of reducing water density by 18% by 2025 ahead of schedule, and further upgraded the target to 30%. The company has more than 12,000 employees from 56 countries around the world, with women accounting for 53% of employees in science, technology, engineering and mathematics (STEM) positions. The company gained mainstream
Yao Ming Kang De: Facing the issue of intellectual property transfer, in 2023 alone, it underwent 748 quality audits from global customers, regulators, and independent third parties, and 83 global customer information security audits
On April 30, Yao Ming Kangde said at the performance exchange meeting that in 2023 alone, the company has received a total of 748 quality audits from global customers, regulators, and independent third parties, and a total of 83 information security audits from global customers (the vast majority from European and American customers). This means that the company undergoes an average of 2 quality audits per day and 7 information security audits per month, and they all meet 100% of the audit requirements and have no major findings. The company's 24 main operating bases have obtained the international standard ISO/IEC 27001 information security management system certification, which includes all
WuXi AppTec: Lower Income From China-Based Customers Weighed on Results >603259.SH
WuXi AppTec: Lower Income From China-Based Customers Weighed on Results >603259.SH
WuXi AppTec 1Q Net CNY1.94B Vs. Net CNY2.17B >603259.SH
WuXi AppTec 1Q Net CNY1.94B Vs. Net CNY2.17B >603259.SH
[Hong Kong Stock Connect] Yao Ming Kangde (02359)'s profit of RMB1,942 billion in the first quarter decreased by 10.42% year-on-year
Jinwu Financial News | Yao Ming Kangde (02359) announced that in the first quarter of 2024, the company's net profit attributable to shareholders of listed companies was 1,942 billion yuan (RMB, same below), a year-on-year decrease of 10.42%; basic earnings per share were 0.67 yuan. In the same period, revenue of 7.982 billion yuan was recorded, a year-on-year decrease of 10.95%.
China Biopharmaceutical (01177): 52 research results will be announced at the 2024 ASCO Annual Meeting
Zhitong Finance App News, China Biopharmaceutical (01177) announced that the Group's Class 1 innovative drugs “anlotinib (small molecule multi-target receptor tyrosine kinase inhibitor)”, “abergastine α (third-generation long-acting G-CSF)”, “piamprizumab (anti-PD-1)” and “FS222 (PD-L1/CD137 double antibody)”, “bemosubimab (anti-PDL1)”, “TQB3617 (BET inhibitor)”, “TQB3728” IAP antagonists), “TQB2930 ( HER2 dual antibody)” will wait until 20
信達生物：2023年報
Hanson Pharmaceuticals (03692): Tan Sihui has been appointed as Joint Company Secretary
Hanson Pharmaceuticals (03692) announced that Li Xinying has resigned as the company's joint company secretary and will no longer serve as the Hong Kong Joint Stock Company...
康方生物：2023 年報
Hanson Pharmaceuticals (03692) will pay a final dividend of HK$0.1422 per share on July 17
Hanson Pharmaceuticals (03692) announced that the company will pay a final dividend of 0 per share on July 17, 2024...
翰森製藥：2023年報